J1652
J1652 – Injection, fondaparinux sodium, 0.5 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 36 NDCs crosswalked per 0.5 MG $0.925/unit ASP+6%
📋 J1652 summary
J1652 is a HCPCS Level II J-code used to bill fondaparinux sodium, 0.5 mg, billed per 0.5 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J1652: Arixtra*, Fondaparinux Sodium, Arixtra
Code J1652
Billing unit 0.5 MG Payment limit $0.925/unit NDC-Crosswalk 36
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ1652
DescriptorInjection, fondaparinux sodium, 0.5 mg
Billing unit0.5 MG
Payment limit / unit$0.925
Est. ASP / unit$0.873 est.
Mapped NDCs36
Data periodQ3 2026
Last updated2026-08-20
💊 About Fondaparinux Injection DRUG GUIDE
Fondaparinux sodium injection is used to prevent deep vein thrombosis (DVT) — blood clots that form in the legs — in adults who are having hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery.
For hip fracture patients, an extended course of prevention is recommended after the initial treatment period.It is also used to treat an existing DVT or acute pulmonary embolism (PE — a clot in the lungs) in adults, always given alongside warfarin sodium until warfarin reaches a therapeutic level.
In pediatric patients aged 1 year and older who weigh at least 10 kg, fondaparinux sodium injection is approved for the treatment of venous thromboembolism (VTE — blood clots in the veins).
Clinical overview from our editorial drug guide for Fondaparinux Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.925
Est. ASP / unit
$0.873 est.
Est. after 2% sequester
$0.907
HCPCS dosage
0.5 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, fondaparinux sodium, 0.5 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2003-01-01
Date added2003-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J1652 = 0.5 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J1652 LEAST EXPENSIVE FIRST
36 NDCs map to J1652. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.925/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 55111-0678-02 | Fondaparinux Sodium 2.5 mg/.5mL INJECTION | Dr. | 2 SYRINGE in 1 CARTON (55111-678-02) / .5... | 2.5 mg/.5mL | 10 | $9.25 | $12.256 | ● Active | CMS ASP |
| 70710-1514-09 | fondaparinux sodium 2.5 mg/.5mL INJECTION, SOLUTION | Zydus | 2 SYRINGE in 1 CARTON (70710-1514-9) / .5... | 2.5 mg/.5mL | 10 | $9.25 | $12.256 | ● Active | CMS + PDAC |
| 55111-0681-02 | Fondaparinux Sodium 10 mg/.8mL INJECTION | Dr. | 2 SYRINGE in 1 CARTON (55111-681-02) / .8... | 10 mg/.8mL | 40 | $37.00 | $18.369 | ● Active | CMS ASP |
| 70710-1517-09 | fondaparinux sodium 10 mg/.8mL INJECTION, SOLUTION | Zydus | 2 SYRINGE in 1 CARTON (70710-1517-9) / .8... | 10 mg/.8mL | 25 | $23.13 | $18.369 | ● Active | PDAC |
| 55111-0680-02 | Fondaparinux Sodium 7.5 mg/.6mL INJECTION | Dr. | 2 SYRINGE in 1 CARTON (55111-680-02) / .6... | 7.5 mg/.6mL | 30 | $27.75 | $20.923 | ● Active | CMS ASP |
| 70710-1516-09 | fondaparinux sodium 7.5 mg/.6mL INJECTION, SOLUTION | Zydus | 2 SYRINGE in 1 CARTON (70710-1516-9) / .6... | 7.5 mg/.6mL | 25 | $23.13 | $20.923 | ● Active | PDAC |
| 00781-3443-95 | Fondaparinux Sodium 2.5 mg/.5mL INJECTION | Sandoz | 10 SYRINGE in 1 CARTON (0781-3443-95) / .... | 2.5 mg/.5mL | 50 | $46.25 | $22.162 | ● Active | CMS + PDAC |
| 55111-0678-10 | Fondaparinux Sodium 2.5 mg/.5mL INJECTION | Dr. | 10 SYRINGE in 1 CARTON (55111-678-10) / .... | 2.5 mg/.5mL | 50 | $46.25 | $22.162 | ● Active | CMS ASP |
| 55150-0230-10 | FONDAPARINUX SODIUM 2.5 mg/.5mL INJECTION, SOLUTION | Eugia | 10 SYRINGE, GLASS in 1 CARTON (55150-230-1... | 2.5 mg/.5mL | 50 | $46.25 | $22.162 | ● Active | CMS + PDAC |
| 67457-0582-10 | Fondaparinux Sodium 2.5 mg/.5mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-582-1... | 2.5 mg/.5mL | 50 | $46.25 | $22.162 | ● Active | CMS + PDAC |
| 70710-1514-06 | fondaparinux sodium 2.5 mg/.5mL INJECTION, SOLUTION | Zydus | 10 SYRINGE in 1 CARTON (70710-1514-6) / .... | 2.5 mg/.5mL | 50 | $46.25 | $22.162 | ● Active | CMS + PDAC |
| 00781-3465-95 | Fondaparinux Sodium 7.5 mg/.6mL INJECTION | Sandoz | 10 SYRINGE in 1 CARTON (0781-3465-95) / .... | 7.5 mg/.6mL | 150 | $138.75 | $42.712 | ● Active | CMS + PDAC |
| 55111-0680-10 | Fondaparinux Sodium 7.5 mg/.6mL INJECTION | Dr. | 10 SYRINGE in 1 CARTON (55111-680-10) / .... | 7.5 mg/.6mL | 150 | $138.75 | $42.712 | ● Active | CMS ASP |
| 55150-0232-10 | FONDAPARINUX SODIUM 7.5 mg/.6mL INJECTION, SOLUTION | Eugia | 10 SYRINGE, GLASS in 1 CARTON (55150-232-1... | 7.5 mg/.6mL | 150 | $138.75 | $42.712 | ● Active | CMS + PDAC |
| 67457-0584-06 | Fondaparinux Sodium 7.5 mg/.6mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-584-0... | 7.5 mg/.6mL | 150 | $138.75 | $42.712 | ● Active | CMS + PDAC |
| 70710-1516-06 | fondaparinux sodium 7.5 mg/.6mL INJECTION, SOLUTION | Zydus | 10 SYRINGE in 1 CARTON (70710-1516-6) / .... | 7.5 mg/.6mL | 25 | $23.13 | $42.712 | ● Active | PDAC |
| 00781-3476-95 | Fondaparinux Sodium 10 mg/.8mL INJECTION | Sandoz | 10 SYRINGE in 1 CARTON (0781-3476-95) / .... | 10 mg/.8mL | 200 | $185.00 | $46.033 | ● Active | CMS + PDAC |
| 55111-0681-10 | Fondaparinux Sodium 10 mg/.8mL INJECTION | Dr. | 10 SYRINGE in 1 CARTON (55111-681-10) / .... | 10 mg/.8mL | 200 | $185.00 | $46.033 | ● Active | CMS ASP |
| 55150-0233-10 | FONDAPARINUX SODIUM 10 mg/.8mL INJECTION, SOLUTION | Eugia | 10 SYRINGE, GLASS in 1 CARTON (55150-233-1... | 10 mg/.8mL | 200 | $185.00 | $46.033 | ● Active | CMS + PDAC |
| 67457-0585-08 | Fondaparinux Sodium 10 mg/.8mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-585-0... | 10 mg/.8mL | 200 | $185.00 | $46.033 | ● Active | CMS + PDAC |
| 70710-1517-06 | fondaparinux sodium 10 mg/.8mL INJECTION, SOLUTION | Zydus | 10 SYRINGE in 1 CARTON (70710-1517-6) / .... | 10 mg/.8mL | 25 | $23.13 | $46.033 | ● Active | PDAC |
| 00781-3454-95 | Fondaparinux Sodium 5 mg/.4mL INJECTION | Sandoz | 10 SYRINGE in 1 CARTON (0781-3454-95) / .... | 5 mg/.4mL | 100 | $92.50 | $55.313 | ● Active | CMS + PDAC |
| 55111-0679-10 | Fondaparinux Sodium 5 mg/.4mL INJECTION | Dr. | 10 SYRINGE in 1 CARTON (55111-679-10) / .... | 5 mg/.4mL | 100 | $92.50 | $55.313 | ● Active | CMS ASP |
| 55150-0231-10 | FONDAPARINUX SODIUM 5 mg/.4mL INJECTION, SOLUTION | Eugia | 10 SYRINGE, GLASS in 1 CARTON (55150-231-1... | 5 mg/.4mL | 100 | $92.50 | $55.313 | ● Active | CMS + PDAC |
| 67457-0583-04 | Fondaparinux Sodium 5 mg/.4mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-583-0... | 5 mg/.4mL | 100 | $92.50 | $55.313 | ● Active | CMS + PDAC |
| 70710-1515-06 | fondaparinux sodium 5 mg/.4mL INJECTION, SOLUTION | Zydus | 10 SYRINGE in 1 CARTON (70710-1515-6) / .... | 5 mg/.4mL | 100 | $92.50 | $55.313 | ● Active | CMS + PDAC |
| 55111-0679-02 | Fondaparinux Sodium 5 mg/.4mL INJECTION | Dr. | 2 SYRINGE in 1 CARTON (55111-679-02) / .4... | 5 mg/.4mL | 20 | $18.50 | — | ● Active | CMS ASP |
| 67457-0592-10 | Arixtra fondaparinux sodium 2.5 mg/.5mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-592-1... | 2.5 mg/.5mL | 50 | $46.25 | — | ● Active | CMS + PDAC |
| 67457-0593-04 | Arixtra fondaparinux sodium 5 mg/.4mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-593-0... | 5 mg/.4mL | 100 | $92.50 | — | ● Active | CMS + PDAC |
| 67457-0594-06 | Arixtra fondaparinux sodium 7.5 mg/.6mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-594-0... | 7.5 mg/.6mL | 150 | $138.75 | — | ● Active | CMS + PDAC |
| 67457-0595-08 | Arixtra fondaparinux sodium 10 mg/.8mL INJECTION, SOLUTION | Mylan | 10 SYRINGE, GLASS in 1 CARTON (67457-595-0... | 10 mg/.8mL | 200 | $185.00 | — | ● Active | CMS + PDAC |
| 00781-3454-12 | Fondaparinux Sodium 5 mg/.4mL INJECTION | Sandoz | 2 SYRINGE in 1 CARTON (0781-3454-12) / .4... | 5 mg/.4mL | 25 | $23.13 | — | ● Active | PDAC |
| 00781-3465-12 | Fondaparinux Sodium 7.5 mg/.6mL INJECTION | Sandoz | 2 SYRINGE in 1 CARTON (0781-3465-12) / .6... | 7.5 mg/.6mL | 25 | $23.13 | — | ● Active | PDAC |
| 00781-3476-12 | Fondaparinux Sodium 10 mg/.8mL INJECTION | Sandoz | 2 SYRINGE in 1 CARTON (0781-3476-12) / .8... | 10 mg/.8mL | 25 | $23.13 | — | ● Active | PDAC |
| 00781-3443-12 | Fondaparinux Sodium 2.5 mg/.5mL INJECTION | Sandoz | 2 SYRINGE in 1 CARTON (0781-3443-12) / .5... | 2.5 mg/.5mL | 10 | $9.25 | — | ● Active | PDAC |
| 70710-1515-09 | fondaparinux sodium 5 mg/.4mL INJECTION, SOLUTION | Zydus | 2 SYRINGE in 1 CARTON (70710-1515-9) / .4... | 5 mg/.4mL | 25 | $23.13 | — | ● Active | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)
Total Part B spend
$502.49
Claims
56
Beneficiaries
20
Spend / beneficiary
$25.12
Spend / claim
$8.97
Where J1652 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #895 of 918
#890
VANCOMYCIN HCL(J3372... J3372
$668.22
#891
PROGESTERONE J2675
$639.25
#892
VASOPRESSIN* J2598
$589.66
#893
NALOXONE HCL(J2310) J2310
$550.85
#894
PARICALCITOL* J2501
$545.05
#895
ARIXTRA* J1652
$502.49
#896
CALDOLOR J1741
$490.39
#897
FLUCONAZOLE-NACL J1450
$477.33
#898
HALOPERIDOL LACTATE J1630
$472.83
#899
CHLORPROMAZINE HCL J3230
$462.84
#900
EPINEPHRINE J0166
$417.15
Total claims — #838 of 918
#833
NOVOEIGHT J7182
63
#834
AMNIOCORE PER SQ CM*... Q4227
63
#835
ABECMA Q2055
61
#836
BIOVANCE 1 SQUARE CM... Q4154
57
#837
FRAGMIN J1645
56
#838
ARIXTRA* J1652
56
#839
TEPADINA(J9340)* J9340
56
#840
TEPADINA(J9342)* J9342
54
#841
DEXAMETHASONE INTENS... J8540
53
#842
CANCIDAS* J0637
52
#843
IXINITY J7213
52
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (1)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2025 (Q1-Q4) | $502.49 | 20 | 56 | $25.12 | $8.97 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$509.75
Medicare paid
$354.83
Submitted services
1,089
Denial rate
34.4%
Allowed / service
$0.71
Submitted charges
$11.7K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J1652 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J1652
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
36 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J1652 billing FAQ
What is HCPCS code J1652?
J1652 is a HCPCS Level II J-code used to bill Injection, fondaparinux sodium, 0.5 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J1652?
One unit of J1652 represents 0.5 MG. Report the number of units equal to the dose administered divided by 0.5 MG.
How many units of J1652 should I bill?
Divide the dose administered by the code's unit size (0.5 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J1652?
The Medicare Part B payment limit is $0.925 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.907 per unit. Payment limits are revised quarterly.
Which NDCs bill under J1652?
36 NDCs currently map to J1652 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J1652 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.